<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436839</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_01833</org_study_id>
    <nct_id>NCT00436839</nct_id>
  </id_info>
  <brief_title>Taxotere Prostate Cancer New Indication Registration Trial in China</brief_title>
  <official_title>An Multicenter, Randomized Study of Comparison of Docetaxel Plus Prednisone With Mitoxantrone Plus Prednisone in the Patients With Hormone-refractory (Androgen-independent) Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and&#xD;
      prednisone in subjects with hormone-refractory metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Overall survival</measure>
    <time_frame>From beginning to end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate of patients with measurable disease by Response Evaluation Criteria in Solid tumours</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostatic Specific Antigen response</measure>
    <time_frame>From the beginning to the end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain response (McGill-Melzack Scale)</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality Of Life: Functional assessment of chronic illness therapy-prostate questionnaire will be used</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m² intravenously (day 1) every 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>12mg/m² intravenously every 21 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>10mg orally given daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone&#xD;
             &lt; 50 ng/dl (ie 1.735 nmol/l)&#xD;
&#xD;
          -  Documented progressive disease&#xD;
&#xD;
          -  Patients should have achieved stable analgesia for 7 days&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70&#xD;
&#xD;
          -  No prior treatment with cytotoxic agent (except estramustine)&#xD;
&#xD;
          -  Normal cardiac function must be confirmed by Left ventricular ejection fraction&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               1. Hematology:&#xD;
&#xD;
                    -  Neutrophils &gt; 1.5 x 10^9/L&#xD;
&#xD;
                    -  Hemoglobin &gt; 10 g/dl. Erythropoietin use is allowed, but red blood cell&#xD;
                       transfusion to upgrade the hemoglobin level is not allowed&#xD;
&#xD;
                    -  Platelets &gt; 100 x 10^9/L&#xD;
&#xD;
               2. Hepatic function:&#xD;
&#xD;
                    -  Total bilirubin &lt; the upper-normal limit of the institution.&#xD;
&#xD;
                    -  Alanine aminotransferase and Aspartate transaminase &lt; 1.5 times the&#xD;
                       upper-normal limit of the institution.&#xD;
&#xD;
               3. Renal function:&#xD;
&#xD;
                    -  Creatinine &lt; 1.5 times the upper normal limit (ie National Cancer&#xD;
                       Institution grade &lt; 1)&#xD;
&#xD;
          -  No brain or leptomeningeal metastases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to &gt;25% of bone marrow (whole pelvic irradiation is not allowed)&#xD;
&#xD;
          -  prior cytotoxic chemotherapy, except monotherapy with estramustine&#xD;
&#xD;
          -  prior isotope therapy&#xD;
&#xD;
          -  history of another cancer within the preceding five year&#xD;
&#xD;
          -  symptomatic peripheral neuropathy grade ≥ 2&#xD;
&#xD;
          -  other serious illness or medical condition:&#xD;
&#xD;
               1. Congestive heart failure even if controlled. Previous history of myocardial&#xD;
                  infarction or angina pectoris within 1 year from study entry, uncontrolled&#xD;
                  hypertension or uncontrolled arrhythmias.&#xD;
&#xD;
               2. Active uncontrolled infection&#xD;
&#xD;
               3. Peptic ulcer, unstable diabetes mellitus or other contraindications for the use&#xD;
                  of corticosteroids.&#xD;
&#xD;
               4. Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)&#xD;
&#xD;
          -  treatment with any other anti-cancer therapy&#xD;
&#xD;
          -  treatment with bisphosphonates&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Fu</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>July 5, 2012</last_update_submitted>
  <last_update_submitted_qc>July 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

